Im with you Avemaria, I think the odds are much better than 50/50. Its a re-purpose drug that has already been approved for other applications. So the unknown is will the results stack up in the phase 3 trials? Im guessing unless American biology is completely different to Australians you would think the results will hold. We have more than 600 Aussies in the SAS program that attest to it, various DR's and OA specialists that love it and have seen the results first hand. I also don't think a prominent American OA Specialist is going to sell his soul for a $ just to promote a drug that does not work and irreparably damage his reputation.
I think the ultimate risk is that it may take a little longer and the "process" more arduous but PR is at least putting the right people to mitigate that. If they don't get revenue's in the short term the longer term risk may be they have to go back to market for another capital raising thus diluting our holdings.
- Forums
- ASX - By Stock
- Current SP appreciation
Im with you Avemaria, I think the odds are much better than...
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M |
Open | High | Low | Value | Volume |
23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 33599 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 65498 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 20000 | 0.230 |
4 | 130009 | 0.225 |
12 | 183076 | 0.220 |
6 | 98958 | 0.215 |
9 | 260864 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 65498 | 1 |
0.245 | 48923 | 2 |
0.250 | 3443 | 1 |
0.260 | 58362 | 1 |
0.270 | 5000 | 1 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online